Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Repros Therapeutics (RPRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 26,413
  • Shares Outstanding, K 26,680
  • Annual Sales, $ 50 K
  • Annual Income, $ -17,270 K
  • 36-Month Beta -0.79
  • Price/Sales 579.01
  • Price/Cash Flow 0.00
  • Price/Book 4.25

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.82 +23.17%
on 04/24/17
1.28 -21.09%
on 04/17/17
-0.20 (-16.53%)
since 03/28/17
3-Month
0.82 +23.17%
on 04/24/17
1.55 -34.84%
on 01/30/17
-0.27 (-21.09%)
since 01/27/17
52-Week
0.82 +23.17%
on 04/24/17
2.57 -60.70%
on 05/19/16
-1.41 (-58.26%)
since 04/28/16

Most Recent Stories

More News
Repros Announces the Issuance of New U.S. Patent Relating to Treatment Using Off Drug Intervals For Certain Uterine Conditions

Repros Therapeutics Inc.(R) (Nasdaq:RPRX) today announced the issuance of a new patent, U.S. Patent number 9,616,074 (the '074 patent), that bolsters the Company's intellectual property relating to Proellex(R)...

RPRX : 1.01 (+2.02%)
Repros' Proellex Continues to be Under Partial Clinical Hold

Repros Therapeutics (RPRX) announced that the FDA will continue to maintain partial clinical hold on its pipeline candidate Proellex for uterine fibroids indication as the agency internally reviews data...

RPRX : 1.01 (+2.02%)
PGNX : 7.90 (+2.33%)
NBIX : 53.41 (-0.34%)
ABBV : 65.88 (-0.29%)
Repros (RPRX) Q4 Earnings: What's in Store for the Stock?

Repros Therapeutics Inc. (RPRX) is expected to report fourth-quarter 2016 results this month.

RPRX : 1.01 (+2.02%)
BMRN : 95.89 (-0.38%)
BMY : 56.08 (+0.74%)
BIIB : 271.30 (-1.91%)
Repros Announces New CEO

Repros Therapeutics Inc. (Nasdaq:RPRX) today announced that Joseph S. Podolski is leaving his position as President and Chief Executive Officer and member of the Board of Directors to pursue other interests....

RPRX : 1.01 (+2.02%)
FDA Grants End of Phase 2 Meeting to Discuss Phase 3 Requirements for Oral Proellex(R) in the Treatment of Uterine Fibroids

Repros Therapeutics Inc. (Nasdaq:RPRX) today announced the FDA has granted an "end of Phase 2" meeting to discuss the Phase 3 requirements to demonstrate both efficacy and safety for the development of...

RPRX : 1.01 (+2.02%)
Repros to Meet with the FDA for Phase III Proellex Program

Repros (RPRX) announced that it has requested a meeting with the FDA to discuss requirements for phase III development of Proellex.

HSKA : 108.27 (+2.90%)
RPRX : 1.01 (+2.02%)
SCMP : 10.23 (+1.24%)
CBM : 59.30 (+1.19%)
Repros Requests Meeting With FDA to Discuss Phase 3 Requirements for Proellex(R) in the Treatment of Symptomatic Uterine Fibroids

-- Focus on oral formulation

RPRX : 1.01 (+2.02%)
FDA Advisory Committee Discusses Clinical Trial Designs for Obesity-Related Hypogonadism

Repros Therapeutics Inc.(R) (Nasdaq:RPRX) participated in the industry presentation at the Bone, Reproductive and Urologic Drugs Advisory Committee Meeting today. The panel provided the FDA with advice...

RPRX : 1.01 (+2.02%)
Repros (RPRX) Reports Positive Top-Line Data on Proellex

Repros Therapeutics Inc. (RPRX) reported top-line results from two phase II studies on its lead pipeline candidate, Proellex, when delivered orally and vaginally for the treatment of uterine fibroids.

ANIK : 46.14 (+0.79%)
RPRX : 1.01 (+2.02%)
INCY : 124.35 (+0.14%)
EXEL : 22.46 (+0.99%)
Repros (RPRX) Loss Narrower Y/Y in Q3, Pipeline in Focus

Repros Therapeutics Inc. (RPRX) reported a loss of 17 cents per share in the third quarter of 2016, significantly narrower than the year-ago loss of 27 cents.

ANIK : 46.14 (+0.79%)
RPRX : 1.01 (+2.02%)
EXEL : 22.46 (+0.99%)
INFI : 2.14 (+1.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Zonagen Inc. is a biopharmaceutical company engaged in the development of products for the human reproductive system, including sexual dysfunction, vaccine adjuvants, products for fertility and female health as well as urological applications, specifically prostate cancer. Zonagen's products to treat...

See More

Support & Resistance

2nd Resistance Point 1.08
1st Resistance Point 1.04
Last Price 1.01
1st Support Level 0.95
2nd Support Level 0.90

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.